Reply to thread

Message: [QUOTE="greenmedinfo, post: 4825"] PMID: Basic Clin Pharmacol Toxicol. 2021 Oct 11. Epub 2021 Oct 11. PMID: 34634189 Abstract Title: The protective effect of solidagenone from Solidago chilensis Meyen in a mouse model of airway inflammation. Abstract: Solidagenone is the main active constituent present in Solidago chilensis Meyen which is used in folk medicine to treat pain and inflammatory diseases. This study aimed to evaluate the anti-inflammatory activity of solidagenone in vitro and in a model of allergic airway inflammation. In vitro studies were performed in activated macrophages and lymphocytes. BALB/c mice were sensitized and challenged with ovalbumin and treated with solidagenone orally (30 or 90 mg/kg body weight) or dexamethasone, as a positive control in our in vivo analysis. Supernatant concentrations of nitrite, TNF and IL-1β, as well as gene expression of pro-inflammatory mediators in macrophages cultures, were reduced after solidagenone treatment, without affecting macrophages viability. Besides, solidagenone significantly decreased T cell proliferation and secretion of IFNγ and IL-2. Th2 cytokine concentrations and inflammatory cell counts, especially eosinophils, in bronchoalveolar lavage fluid were reduced in mice treated with solidagenone. Histopathological evaluation of lung tissue was performed, and morphometrical analyses demonstrated reduction of cellular infiltration and mucus hypersecretion. Altogether, solidagenone presented anti-inflammatory activity in vitro and in vivo in the OVA-induced airway inflammation model, suggesting its promising pharmacologicaluse as an anti-inflammatory agent for allergic hypersensitivity. [URL='https://www.greenmedinfo.com/article/protective-effect-solidagenone-solidago-chilensis-meyen-mouse-model-airway-inf']read more[/URL] [/QUOTE]

Verification

Top Bottom

Search

Search

Reply to thread